Skip to main content

Table 4 Univariate Cox regression analysis of the impact of the lncRNA signature and other clinicopathological features on OS in the three NSCLC patient cohorts

From: Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China

Parameters Training cohort Validation cohort Independent cohort
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Signature
 (High vs low) 3.20 (0.58–1.65) < 0.001 2.84 (1.59–5.07) < 0.001 2.84 (1.59–5.07) 0.009
Age
 (≥ 60 vs < 60) 1.24 (0.73–2.09) 0.417 1.13 (0.67–1.91) 0.330 0.88 (0.36–2.13) 0.782
Gender
 (Male vs female) 0.86 (0.48–1.52) 0.619 1.24 (0.63–2.41) 0.050 0.98 (0.37–2.57) 0.978
TNM stages
 (III vs II vs I) 1.67 (1.28–2.19) < 0.001 1.70 (1.30–2.23) 0.001 1.74 (1.04–2.89) 0.031
Histological type
 (ADC vs SCC) 1.30 (0.74–2.29) 0.346 1.39 (0.82–2.36) 0.589 0.53 (0.15–1.83) 0.320
Tumor size
 (≥ 5 cm vs < 5 cm) 1.17 (0.69–1.98) 0.545 1.15 (0.68–1.95) 0.017 3.00 (1.00–9.00) 0.048
Differentiation
 (Poor vs well/mod) 0.98 (0.58–1.65) 0.951 1.43 (0.85–2.42) 0.079 1.80 (0.74–4.32) 0.188
Lymph metastasis
 (Yes vs no) 1.44 (0.86–2.43) 0.163 0.73 (0.43–1.24) 0.025 1.38 (0.46–4.14) 0.561
Smoking history
 (Yes vs no) 0.91 (0.54–1.54) 0.736 1.63 (0.92–2.91) 0.024 1.11 (0.46–2.68) 0.812
Fam. cancer hist.
 (Yes vs no) 1.04 (0.52–2.06) 0.899 1.18 (0.58–2.42) 0.580 0.47 (2.97–7.64) 0.618
  1. Italic P values represent the statistic significance
  2. Fam. cancer hist. Family cancer history